M&A Deal Summary

FSD Acquires Prismic Pharmaceuticals

On April 23, 2019, FSD acquired life science company Prismic Pharmaceuticals for 18M USD

Acquisition Highlights
  • This is FSD’s 1st transaction in the Life Science sector.
  • This is FSD’s largest (disclosed) transaction.
  • This is FSD’s 1st transaction in the United States.
  • This is FSD’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2019-04-23
Target Prismic Pharmaceuticals
Sector Life Science
Buyer(s) FSD
Deal Type Add-on Acquisition
Deal Value 18M USD

Target

Prismic Pharmaceuticals

Worcester, Massachusetts, United States
Prismic Pharmaceuticals, Inc. is a pharmaceutical company dedicated to addressing the opioid crisis by developing novel non-addictive prescription drugs for the treatment of pain, inflammation, and neurological disorders, based on formulations utilizing the company’s micro-PEA development platform (palmitoylethanolamide with particle sizes of 0.6 – 10 microns). Prismic Pharmaceuticals, Inc. was founded in 2011 and is based in Worcester, Massachusetts.

Search 198,123 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

FSD

Toronto, Ontario, Canada
Category Company
Founded 1998
Sector Life Science
Employees9
DESCRIPTION

FSD is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation license on October 13, 2017. FV Pharma management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. FSD was founded in 1998 and is based in Toronto, Canada.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-25 Lucid Psycheceuticals

Toronto, Ontario, Canada

Lucid Psycheceuticals is a specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases. The company's team is composed of highly specialized science experts focused on providing leading-edge small molecule therapeutics for total brain health. Lucid Psycheceuticals is based in Toronto, Ontario.

Buy $9M
Mergr

Product

Company

Legal